Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges - Wikidata - awgldk - TriplyDB

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

http://www.wikidata.org/entity/Q38878906

about

Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer Immunotherapy of colorectal cancer: new perspectives after a long path.Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab.Part II: Checkpoint inhibitors in cancer therapy.Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy.New horizons from immunotherapy in malignant pleural mesothelioma.High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma.Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.Fusogenic Viruses in Oncolytic Immunotherapy Engineering CAR-T Cells for Improved Function Against Solid Tumors

P2860

Q28066486-C7FBFC5A-4D3B-4D23-81B3-409EB198976A Q39043413-15785CB0-4D9D-44C6-AC23-4F441AF23883 Q42968783-A54178E2-5E7F-41C5-85EB-279A3BC83336 Q46307584-D36B6B1F-7926-4EFB-B627-35AFF333B8A1 Q47098333-18088611-687E-4E9E-B2B7-F0684D67BD3F Q47916852-83FE69C8-D6D4-47DD-86C6-01B037AA5205 Q52606149-E1AA8DF2-3E6F-47D2-B4DA-C6041C840BEF Q52672888-779B3752-B4BE-482F-8AD6-668099F75CC2 Q52677218-B456A904-14EB-4603-BA7F-AD831DE94DC2 Q53068034-FD77787F-69EC-4F3F-A51F-AC762D1B5408 Q56971929-C3B2562E-8EDA-4A45-8F4D-0C027D33C50A Q58694793-3C76E829-2233-45D2-91AF-F23FF4EE5894

P2860

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

http://www.wikidata.org/entity/Q38878906

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

@en

type

label

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

@en

prefLabel

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

@en

P1433

Q38878906-CCF6B156-B868-4506-89FB-5C95E65558F7

P1476

Q38878906-76E205CD-380F-4E68-9B7F-29E3827B3E6B

P2093

Q38878906-46F0B7A5-662F-45F8-87A0-66D7BCF3E18E

Q38878906-BEF3F36E-E84A-4DF1-BEA3-E3B78714B696

P2860

Q38878906-00516E07-90ED-402F-854F-B697D42B5C3F

Q38878906-01DBC69E-E045-494C-BA63-5EEA8A170B25

Q38878906-05CEE800-2332-4349-B9F0-29619220C5E0

Q38878906-083B5A90-A25D-4DED-B787-5E1C2496B7E7

Q38878906-0BA460F8-5558-4F35-A1BC-F98B4E9E3087

Q38878906-0EEF2219-5CFA-491B-8E2E-479458FC6BC8

Q38878906-0F6A1823-4548-4B6A-9A41-A179868FA52D

Q38878906-106C1196-CF28-4E6F-A6FC-64A1F7A47A10

Q38878906-11D8CB5B-45DC-41F7-A05D-8134B9E98204

Q38878906-12D12C89-D96A-42B0-8002-5F24A7902F9A

P304

Q38878906-CF5E279D-611D-4B9B-8D05-12F1AB14BEC5

P31

Q38878906-F4D4D2A8-9C77-4D9E-8E7D-309DF76C46F0

P356

Q38878906-6B3B8E00-52F9-4F81-B4AA-DE4451C93204

P433

Q38878906-9FDDD86E-0825-4FAB-AE0A-EEC216A395B0

P478

Q38878906-C323D16E-47BD-42DA-AFB1-323E9A3320FA

P577

Q38878906-5E55DC7E-22E5-43D8-8086-AFE8EE52059F

P698

Q38878906-FD9539E9-FDC0-4D99-9F95-8DAA902B39BC

P932

Q38878906-9FEC2EDD-61B8-49E6-8DBB-DE133AF4DBCD

P356

P1433

P1476

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

@en

P2093

Chrisann Kyi

http://www.w3.org/2001/XMLSchema#string

Michael A Postow

http://www.w3.org/2001/XMLSchema#string

P2860

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity

Immune Checkpoint Blockade in Cancer Therapy

Science gone translational: the OX40 agonist story

Nivolumab plus ipilimumab in advanced melanoma.

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

P304

821-837

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2016-0002

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27349981

http://www.w3.org/2001/XMLSchema#string

P932

5619130

http://www.w3.org/2001/XMLSchema#string